Anti-FGF2/ BFGF/ FGF-2 functional antibody

Anti-FGF2/ BFGF/ FGF-2 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to FGF2/FGF2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T31621-Ab-1/ GM-Tg-hg-T31621-Ab-2Anti-Human FGF2 monoclonal antibodyHuman
GM-Tg-rg-T31621-Ab-1/ GM-Tg-rg-T31621-Ab-2Anti-Rat FGF2 monoclonal antibodyRat
GM-Tg-mg-T31621-Ab-1/ GM-Tg-mg-T31621-Ab-2Anti-Mouse FGF2 monoclonal antibodyMouse
GM-Tg-cynog-T31621-Ab-1/ GM-Tg-cynog-T31621-Ab-2Anti-Cynomolgus/ Rhesus macaque FGF2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T31621-Ab-1/ GM-Tg-felg-T31621-Ab-2Anti-Feline FGF2 monoclonal antibodyFeline
GM-Tg-cang-T31621-Ab-1/ GM-Tg-cang-T31621-Ab-2Anti-Canine FGF2 monoclonal antibodyCanine
GM-Tg-bovg-T31621-Ab-1/ GM-Tg-bovg-T31621-Ab-2Anti-Bovine FGF2 monoclonal antibodyBovine
GM-Tg-equg-T31621-Ab-1/ GM-Tg-equg-T31621-Ab-2Anti-Equine FGF2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T31621-Ab-1/ GM-Tg-hg-T31621-Ab-2; GM-Tg-rg-T31621-Ab-1/ GM-Tg-rg-T31621-Ab-2;
GM-Tg-mg-T31621-Ab-1/ GM-Tg-mg-T31621-Ab-2; GM-Tg-cynog-T31621-Ab-1/ GM-Tg-cynog-T31621-Ab-2;
GM-Tg-felg-T31621-Ab-1/ GM-Tg-felg-T31621-Ab-2; GM-Tg-cang-T31621-Ab-1/ GM-Tg-cang-T31621-Ab-2;
GM-Tg-bovg-T31621-Ab-1/ GM-Tg-bovg-T31621-Ab-2; GM-Tg-equg-T31621-Ab-1/ GM-Tg-equg-T31621-Ab-2
Products NameAnti-FGF2 monoclonal antibody
Formatmab
Target NameFGF2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FGF2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-820Pre-Made Eflimrufusp Alfa Biosimilar, Fusion Protein targeting FGF2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BFGF/FGF-2/FGFB/HBGF-2
    BiosimilarGMP-Bios-INN-969Pre-Made Recifercept biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting FGF
    Target AntigenGM-Tg-g-T31621-Ag-1Recombinant multi-species FGF2/ BFGF/ FGF-2 protein
    CytokineGM-Tg-g-T31621-Ag-1fibroblast growth factor 2 (basic) (FGF2) protein
    ORF Viral VectorvGMLV000801human FGF2 Lentivirus particle
    ORF Viral VectorvGMAD000136human FGF2 Adenovirus particle
    ORF Viral VectorpGMAD000136human FGF2 Adenovirus plasmid
    ORF Viral VectorpGMLV000801human FGF2 Lentivirus plasmid
    ORF Viral VectorpGMAD000296rat Fgf2 Adenovirus plasmid
    ORF Viral VectorpGMLPm000253mouse Fgf2 Lentivirus plasmid
    ORF Viral VectorvGMAD000296rat Fgf2 Adenovirus particle
    ORF Viral VectorvGMLPm000253mouse Fgf2 Lentivirus particle


    Target information

    Target IDGM-T31621
    Target NameFGF2
    Gene ID2247,14173,54250,574136,403857,100135772,281161,100033955
    Gene Symbol and SynonymsBFGF,FGF-2,FGF2,Fgf2a,FGFB,HBGF-2
    Uniprot AccessionP09038,P13109,P03969
    Uniprot Entry NameFGF2_HUMAN,FGF2_RAT,FGF2_BOVIN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseBreast Cancer
    Gene EnsemblENSG00000138685
    Target ClassificationCheckpoint-Immuno Oncology

    The target: FGF2, gene name: FGF2, also named as BFGF, FGF-2, FGFB, HBGF-2. The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.